Swan Valley Medical, Incorporated
The T-SPeC® is an FDA and CE medical device in a multi-billion dollar market worldwide, with no comparable devices with beginning sales.
T-SPeC® is targeted at replacing the percutaneous cystostomy that has an unacceptable 4.4% average mortality rate and 29% morbidity rate. T-SPeC® has 0% morbidity and 1.6% complication rate. The use of T-SPeC® will lower infection rates (CAUTI) by 64%, generate revenue for hospital and dramatically improve patient quality of life.